Detalles de la búsqueda
1.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38012435
2.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474619
3.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30892724
4.
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Ann Hematol
; 98(8): 1885-1890, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31044260
5.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674504
6.
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Ann Hematol
; 97(1): 95-100, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28971265
7.
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.
Support Care Cancer
; 24(11): 4487-93, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27260015
8.
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia.
Am J Hematol
; 93(7): E162-E164, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29633310
9.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Am J Hematol
; 93(7): E159-E161, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29633312
10.
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients.
Patient Prefer Adherence
; 16: 2963-2975, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36338243
11.
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
Int J Cardiol
; 301: 163-166, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31711851
12.
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cancer Med
; 9(22): 8468-8479, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32969597
13.
Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial.
Front Psychol
; 10: 329, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30842749
14.
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population.
Mediterr J Hematol Infect Dis
; 11(1): e2019025, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31205629
15.
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
Int J Cardiol
; 288: 124-127, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31029498
16.
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Oncotarget
; 6(32): 33944-51, 2015 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26376678
17.
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Blood Cancer J
; 10(6): 66, 2020 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32514110
18.
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
Leuk Lymphoma
; 58(7): 1764-1766, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27892750
Resultados
1 -
18
de 18
1
Próxima >
>>